Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab

Main Article Content

Kim A Papp
Andrew Blauvelt
Mary Flack
Yihua Gu
Elizabeth HZ Thompson

Keywords

psoriasis, risankizumab, ustekinumab, biologic therapy

Abstract

Abstract Not Available

 

Disclosures: Study supported by AbbVie.